Research programme: monoclonal antibody therapeutics - Integral molecular

Drug Profile

Research programme: monoclonal antibody therapeutics - Integral molecular

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Integral Molecular
  • Class Monoclonal antibodies
  • Mechanism of Action GLUT4 stimulants; Immunomodulators; Membrane protein modulators; Purinergic P2X3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Chikungunya virus infections; Ebola virus infections; Neuropathic pain; Type 2 diabetes mellitus; Zika virus infection

Most Recent Events

  • 16 Nov 2016 Early research in Zika virus infection in USA (unspecified route)
  • 10 Feb 2016 Integral Molecular has patent protection for Lipoparticle technology in USA and Europe
  • 01 Apr 2015 Early research in Ebola virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top